Maxim analyst Jason McCarthy upgraded Reviva Pharmaceuticals (RVPH) to Buy from Hold with a $7 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH:
- Reviva Pharmaceuticals initiated with a Buy at Roth MKM
- Reviva Pharmaceuticals Strengthens Financial Position with Offering
- Reviva Pharmaceuticals 12M share Spot Secondary priced at $1.50
- Reviva Pharmaceuticals announces common stock, warrant offering, no amount given
- Reviva Pharmaceuticals Reports Positive Phase 3 Trial Results